Virtual Library

Start Your Search

Luis Antunes



Author of

  • +

    P2.12 - Small Cell Lung Cancer/NET (ID 180)

    • Event: WCLC 2019
    • Type: Poster Viewing in the Exhibit Hall
    • Track: Small Cell Lung Cancer/NET
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall
    • +

      P2.12-19 - Small Cell Lung Cancer (SCLC) Treatment and Survival in Portugal: An IPO-PORTO Analysis from the I-O Optimise Initiative (ID 1762)

      10:15 - 18:15  |  Author(s): Luis Antunes

      • Abstract

      Background

      Approximately 15% of lung cancers are SCLC, which is an aggressive disease associated with poor patient outcomes and limited treatment options. As part of I-O Optimise, a multinational research platform providing insights into the real-world management of thoracic malignancies, the IPO-PORTO study aimed to characterise treatment options and their impact on overall survival (OS) in patients diagnosed with SCLC in Portugal’s largest oncology hospital.

      Method

      IPO-PORTO collects data on patients with various cancers and is linked to the North Region Cancer Registry (RORENO), covering Northern Portugal. This analysis included all adult patients diagnosed with non-resected limited disease (LD)- or incident extensive disease (ED)-SCLC at IPO-PORTO between January 2012 and June 2017, with follow-up to December 2017. ED was defined as metastatic because Veterans Administration Lung Study Group staging was not available. Systemic anti-cancer therapy (SACT) information was available from 2015 onwards. Bespoke and clinically validated rule-based algorithms were applied to describe treatment patterns. The Kaplan–Meier method was used to estimate OS.

      Result

      Of 227 patients diagnosed with incident SCLC, 61 (26.9%) had non-resected LD and 166 (73.1%) had ED. Median age was 65 years (range: 59–72) and most patients (83.7%) were male. Most patients with LD-SCLC had stage IIIA/IIIB disease (78.7%). Sites of metastasis in ED-SCLC were bone (47.6%), liver (45.2%), lymph nodes (17.5%), or brain/CNS (13.3%). In patients diagnosed with LD-SCLC from 2015 onwards, 16 of 25 (64.0%) received SACT; among these, 11 received SACT associated with radiotherapy (68.8%). In patients diagnosed with ED-SCLC from 2015 onwards, 53 of 83 (63.9%) were treated with SACT. Among the 69 patients treated with SACT after diagnosis, only 9 received 2nd-line treatment (13.0%). Almost all patients received a platinum-based regimen including cisplatin or carboplatin and etoposide as 1st-line treatment. In patients diagnosed from 2012 onwards, the 1-year OS rate was 54% (95% CI, 43–69) for patients with LD-SCLC and 17% (95% CI, 12–24) for ED-SCLC. Among treated patients with ED-SCLC who were diagnosed from 2015 onwards, the 1-year OS rate was 18% (95% CI, 9–35).

      Conclusion

      Patients with SCLC had a high disease burden; most patients were diagnosed with ED and nearly three-quarters died within a year of diagnosis. The study confirmed that the majority of ED-SCLC patients diagnosed at IPO-PORTO after 2015 were treated with SACT; despite this, 1-year OS rates remained low (<20%).